Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: Ramosetronvs granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy

  • Brief Report
  • Published:
Canadian Journal of Anesthesia/Journal canadien d'anesthésie Aims and scope Submit manuscript

This article was retracted on 27 April 2013

Abstract

Purpose

To compare the efficacy of ramosetron with granisetron for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy.

Methods

In a randomized, double-blind study, 80 female inpatients received 3 mg granisetron or 0.3 mg ramosetroniv (n=40 of each) at the completion of surgery The standardized anesthetic included isoflurane and nitrous oxide in oxygen.

Results

Complete response, defined as no PONV during the first 24 hr (0–24 hr) after anesthesia was 85% with granisetron and 93% with ramosetron, respectively (P=0.241); the corresponding incidence during the next 24 hr (24–48 hr) after anesthesia was 63% and 90% (P=0.004). No clinically important adverse events due to the study drug were observed in any of the groups.

Conclusion

Ramosetron was more effective than granisetron for prevention of PONV during 0–48 hr after anesthesia for laparoscopic cholecystectomy.

Résumé

Objectif

Comparer l’efficacité du ramosétron et du granisétron dans la prévention des nausées et des vomissements postopératoires (NVPO) à la suite d’une cholécystectomie laparoscopique.

Méthode

L’étude randomisée, à double insu, a porté sur 80 femmes qui ont reçu 3 mg de granisétron ou 0,3 mg de ramosétroniv (n=40 dans chaque cas) après l’opération. Lanesthésie standard comprenait de l’isoflurane et un mélange de protoxyde d’azote et d’oxygène.

Résultats

La réponse complète, définie comme une absence de NVPO, a été de 85% avec le granisétron et de 93% avec le ramosétron, respectivement (P=0,241), pendant les 24 premières heures postanesthésiques (0–24 h); pendant les 24 h suivantes, l’incidence correspondante a été de 63% et de 90% (P=0,004). Aucun événement indésirable, d’importance clinique et relié aux médicaments de l’étude, n’est survenu.

Conclusion

Le ramosétron a été plus efficace que le granisétron à prévenir les NVPO pendant les 48 premières heures qui ont suivi la cholécystectomie laparoscopique.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fujii Y, Tanaka H, Toyooka H. Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 1997; 44: 396–400.

    Article  PubMed  CAS  Google Scholar 

  2. Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Anti-emetic efficacy of prophylactic graniserton, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. Eur J Anesthesiol 1988; 15: 166–71.

    Google Scholar 

  3. Fujibara A, Akuzawa S, Miyata K, Miyake A. Ramosetron hydrochloride: affinity for cloned human 5-HT3 receptor and 5-HT3 receptor antagonistic and antiemetic effect in the ferret. (Japanese) Kiso to Rinsho 1996; 30: 1965–72.

    Google Scholar 

  4. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.

    Article  PubMed  CAS  Google Scholar 

  5. Bermudez J, Boyle EA, Minter WD, Sanger GJ. The antiemetic potential of the 5hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.

    Article  PubMed  CAS  Google Scholar 

  6. Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.

    Article  PubMed  CAS  Google Scholar 

  7. Noda K, Ikeda M, Yoshida O, et al. Clinical evaluation of ramosetron against the nausea and vomiting induced by anticancer drugs. (Japanese) Jpn J Clin Exp Med 1994; 71: 2765–76.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anaesthesiology, University of Tsukuba Institute of Clinical Medicine, 2-1-1, Amakubo, Tsukuba City, 305, Ibaraki, Japan

    Yoshitaka Fujii & Hidenori Toyooka

  2. Department of Anaesthesiology, Toride Kyodo General Hospital, Toride City, Ibaraki, Japan

    Yuhji Saitoh & Hiroyoshi Tanaka

Authors
  1. Yoshitaka Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuhji Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyoshi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hidenori Toyooka
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

A retraction note to this article is available at http://dx.doi.org/10.1007/s12630-013-9947-1.

This article has been retracted due to two reasons: Many variables reported in the studies are exceedingly unlikely. The author's institution is not able to attest to the integrity of the study and/or the data conducted under its auspices.

An erratum to this article is available at http://dx.doi.org/10.1007/s12630-013-9947-1.

About this article

Cite this article

Fujii, Y., Saitoh, Y., Tanaka, H. et al. RETRACTED ARTICLE: Ramosetronvs granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Can J Anesth/J Can Anesth 46, 991–993 (1999). https://doi.org/10.1007/BF03013138

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03013138

Keywords

Search

Navigation